Your session is about to expire
← Back to Search
Peptide
ALT-801 for Non-alcoholic Fatty Liver Disease
Phase 1
Waitlist Available
Research Sponsored by Altimmune, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Written informed consent to participate in this extension study, signed prior to the performance of any study procedures
Receipt of 12 weeks of investigational product with completion of the procedures in Study ALT-801-105
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 110
Awards & highlights
Study Summary
This trial will study the safety and effects of a drug on obese people with diabetes and fatty liver disease.
Eligible Conditions
- Non-alcoholic Fatty Liver Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to day 110
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 110
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Secondary outcome measures
Change from baseline in body weight
Change from baseline in fibrosis markers (Pro-C3)
Change from baseline in hemoglobin A1c
+2 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: ALT-801 Dose Level 3Experimental Treatment1 Intervention
Administered once a week for 12 weeks
Group II: ALT-801 Dose Level 2Experimental Treatment1 Intervention
Administered once a week for 12 weeks
Group III: ALT-801 Dose Level 1Experimental Treatment1 Intervention
Administered once a week for 12 weeks
Group IV: PlaceboPlacebo Group1 Intervention
Administered once a week for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALT-801
2010
Completed Phase 2
~770
Find a Location
Who is running the clinical trial?
Altimmune, Inc.Lead Sponsor
16 Previous Clinical Trials
1,474 Total Patients Enrolled
4 Trials studying Non-alcoholic Fatty Liver Disease
425 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Sarah K Browne, MDStudy DirectorAltimmune, Inc.
2 Previous Clinical Trials
486 Total Patients Enrolled
1 Trials studying Non-alcoholic Fatty Liver Disease
95 Patients Enrolled for Non-alcoholic Fatty Liver Disease
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger